drugset / Trial / NCT01491971

Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients With Prostate Cancer

NCT01491971

Phase 2 Completed 76 enrolled Ferring Pharmaceuticals
RandomizedParallel-groupOpen-labelTreatment

Summary

Intramuscular Injections of Degarelix Administered in 1-Month Dosing Regimens in Patients with Prostate Cancer.

Timeline

Start
2012-01
Primary completion
2012-11
Completion
2012-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Degarelix Other / unclassified Intramuscular

Indications